ArticleIntensive care medicine2021
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
Article in Intensive care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 158 citations in OpenAlex.
- Portable electronic bronchoscopy for clinical application: a multi-institutional randomized instrument validation study.The Journal of international medical research · 2022Trial
- Unclassifiable Invasive Pulmonary Aspergillosis in the Intensive Care Unit: Insights From a Multicenter, Retrospective Cohort Study in France (2022-2024).Open forum infectious diseases · 2026Article
- Mechanistic Insights Into Acute Kidney Injury Complicating Invasive Pulmonary Aspergillosis in Adults.Cureus · 2026Review
- Delayed intubation and 60-day mortality in severe COVID-19-associated acute respiratory failure in an emulated target trial using the OUTCOMEREA network.Scientific reports · 2026Article
- Article
- Invasive pulmonary aspergillosis among ICU patients with COVID-19, influenza, and preexisting host factors: a nationwide cohort study.BMC infectious diseases · 2026Article
- Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.Journal of thoracic disease · 2026Article
- Development and Internal Validation of a Nomogram Model to Predict Invasive Pulmonary Aspergillosis Occurrence Risk in ICU Patients with Sepsis.Infection and drug resistance · 2026Article
- Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024.Antimicrobial agents and chemotherapy · 2025Article
- Risk and prognostic patterns of viral-associated invasive pulmonary aspergillosis: impact of corticosteroid and antibiotic exposure in non-neutropenic hosts.Journal of thoracic disease · 2025Article
- Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.Journal of food and drug analysis · 2025Review
- Article
- Characterization of the gut microbiota in drug abuse: prediction, prevention, and personalized medicine to benefit affected populations.The EPMA journal · 2025Review
- The Patterns and Appropriateness of Systemic Antifungal Prescriptions in a Regional Hospital in Hong Kong.Antibiotics (Basel, Switzerland) · 2025Article
- Impact of physician awareness and microbiological examination on incidence of COVID-19-associated pulmonary aspergillosis: a retrospective study.BMC pulmonary medicine · 2025Article
- An Observational Cohort Study of Bronchoalveolar Lavage Fluid Galactomannan andOpen forum infectious diseases · 2025Article
- Treatment of Post-COVID-19 Pulmonary Aspergilloma: Insights from a Clinical Case.The American journal of case reports · 2025Article
- Epidemiology of Coronavirus Disease 2019-Associated Fungal Infections in the Intensive Care Unit: A Single-Center Retrospective Study.Mycopathologia · 2025Article
- Appraisal of guidelines and variations in recommendations on drug therapy for invasive aspergillosis prevention and treatment.Frontiers in pharmacology · 2025Article
- Clinical characteristics and prognosis of COVID-19- associated invasive pulmonary aspergillosis in critically patients: a single-center study.Frontiers in cellular and infection microbiology · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 20 institutions in 12 countries.
Funding
Abstract
purposeInvasive pulmonary aspergillosis (IPA) is increasingly reported in patients with severe coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Diagnosis and management of COVID-19 associated pulmonary aspergillosis (CAPA) are challenging and our aim was to develop practical guidance.
methodsA group of 28 international experts reviewed current insights in the epidemiology, diagnosis and management of CAPA and developed recommendations using GRADE methodology.
resultsThe prevalence of CAPA varied between 0 and 33%, which may be partly due to variable case definitions, but likely represents true variation. Bronchoscopy and bronchoalveolar lavage (BAL) remain the cornerstone of CAPA diagnosis, allowing for diagnosis of invasive Aspergillus tracheobronchitis and collection of the best validated specimen for Aspergillus diagnostics. Most patients diagnosed with CAPA lack traditional host factors, but pre-existing structural lung disease and immunomodulating therapy may predispose to CAPA risk. Computed tomography seems to be of limited value to rule CAPA in or out, and serum biomarkers are negative in 85% of patients. As the mortality of CAPA is around 50%, antifungal therapy is recommended for BAL positive patients, but the decision to treat depends on the patients' clinical condition and the institutional incidence of CAPA. We recommend against routinely stopping concomitant corticosteroid or IL-6 blocking therapy in CAPA patients.
conclusionCAPA is a complex disease involving a continuum of respiratory colonization, tissue invasion and angioinvasive disease. Knowledge gaps including true epidemiology, optimal diagnostic work-up, management strategies and role of host-directed therapy require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.